Capital Network: Optibiotix Health - Microbiome Specialist Entering Commercial Phase
OptiBiotix Health Plc (LON:OPTI) focuses on managing and treating widespread, chronic medical conditions, such as obesity and high cholesterol, through the modulation of the human microbiome.
OptiBiotix Health is a life sciences company operating in one of the areas of biotechnological research, the modulation of the Human Microbiome. Co. is working on microbiotics by discovering and developing microbial strains, compounds and formulations which modulate the human microbiome and effect on lipid and cholesterol management, energy harvest and appetite suppression fuelled by its proprietary OptiScreen® and OptiBiotic® platforms to bring health benefits.
Capital Network is the foremost authority on utilising digitisation to allow companies to achieve their corporate goals, whether those goals pertain to raising capital, increasing investor awareness, boosting liquidity or allowing the business to flourish. We are proud to deliver bespoke, industry-leading services to a broad range of capital market clients. To deliver on our range of digitised services clients are assigned tier-1 analysts who have extensive sector knowledge, numerous accreditations and a track record of delivering success.
The investor community is evolving and we allow investment banks, fund managers, hedge funds, wealth managers, trusts, family offices and private investors the capacity to access new investment ideas as well delivering further insight into their current portfolio. In addition to driving value for our diverse client base, we empower investors with our digital solutions.
Our approach to serving clients takes a traditional method of doing first-class business in a first-class way, in conjunction with implementing the most technologically advanced services for them. We strive to build trusted, long-term relationships built on diligence and foresight, and identifying ways to help clients achieve their most important business objectives.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.